|Former: Atención Farmacéutica|
|Journal edited by Rasgo Editorial since 1983|
Maruxa Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Tomás Casasín Edo
María B. Badía Tahull
Lluís Campins Bernadas
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 22 - Issue 2, April-June 2020
BIOLOGICAL TREATMENTS IN RHEUMATOLOGY AFTER THE INTRODUCTION OF AN ETANERCEPT BIOSIMILAR
PRIETO CASTELLÓ MANUEL, SARRIÓ MONTES GEMA, SÁNCHEZ ALCARÁZ AGUSTÍN
Objective: Evaluate the use of the different alternatives available for the treatment of rheumatologic diseases in a rheumatology service before and after the introduction of biosimilar etanercept.
Method: A retrospective observational study of the prescription of biological drugs was carried out
in the first line after the introduction of a etanercept biosimilar in the Rheumatology Service.
Results: After the introduction of the biosimilar of etanercept, a reduction in the prescription of
etanercept was observed, which went from being the first choice by physicians in 38.9% of cases to
9.5%. However, there is an increase in the prescription of secukinumab, which went from not being
used in the first line to being the most used (28.6%) together with baricitinib (28.6%) that was
previ- ously only prescribed in 5.6% of cases, assuming this a change not only of the drug used but
also of the target of action chosen by the physician.
Conclusions: Training in biosimilars in the hospital will be promoted to raise awareness among prescribing physicians about the similarity of the biosimilar drug to the reference drug and its efficiency for the national health system.
BIOSIMILAR – COSTS – ETANERCEPT